Three anticancers get first CHMP nods
This article was originally published in Scrip
The EU's CHMP granted positive opinions at its latest meeting this week to three new medicines to treat cancer: Dendreon's Provenge (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or Sipuleucel-T); GlaxoSmithKline's Tafinlar (dabrafenib); and Bayer's Stivarga (regorafenib). All three products have already received their first marketing approvals in the US.
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.